Key facts
- JPMorgan downgraded Daiichi Sankyo's stock rating.
- The downgrade was based on a weak company outlook.
JPMorgan has announced a reduction in its stock rating for the pharmaceutical company Daiichi Sankyo. The decision stems from an assessment of the company's future prospects, which JPMorgan views as weak. This downgrade suggests that analysts at JPMorgan anticipate a less favorable financial performance from Daiichi Sankyo in the upcoming periods.